Organization (Industry)
ITALFARMACO S.P.A.
ClinicalTrials.gov lists ITALFARMACO S.P.A. as lead sponsor of 53 trials, counting the companies grouped under it. ITALFARMACO S.P.A. itself has 13 active development programs and 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers ITALFARMACO S.P.A. and 3 companies grouped under it: 53 lead-sponsored trials (36 its own, 17 in the grouped companies) and 9 legal-entity registrations (4 its own, 5 in the grouped companies).
Companies grouped under this page (3)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| LACER S.A. | 13 | 2 |
| CHEMI - S.P.A. | 4 | 2 |
| ITF RESEARCH PHARMA, S.L. | 0 | 1 |
Disease areas (24)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Muscular Dystrophy, Duchenne | 9 |
| Hematologic Neoplasms | 5 |
| Polycythemia Vera | 5 |
| Gingivitis | 3 |
| Primary Myelofibrosis | 3 |
Showing 5 of 24 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 2 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 2 |
| 2014 | 1 |
| 2013 | 4 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (13)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Givinostat | Muscular Dystrophy, Duchenne | Phase 3 | 6 |
| Givinostat | Hematologic Neoplasms | Phase 3 | 3 |
| Givinostat | Polycythemia Vera | Phase 3 | 3 |
| HYDROXYUREA | Polycythemia Vera | Phase 3 | 1 |
| HYDROXYUREA | Hematologic Neoplasms | Phase 3 | 1 |
Showing 5 of 13 active programs.
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Female Contraceptive | 1 |
| Givinostat | 13 |
| Estriol | 1 |
| HYDROXYUREA | 1 |
| Nadroparin | 1 |
Showing 5 of 9 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=5) | 20% on time (n=5) |
Journals published in (32)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Lancet. Neurology | 4 |
| American journal of obstetrics and gynecology | 3 |
| The American journal of clinical nutrition | 3 |
| The Cochrane database of systematic reviews | 3 |
| Journal of sex & marital therapy | 2 |
Showing 5 of 32 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 99 | 3 | 2024-10-29 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 6 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Italfarmaco SPA | Milan, IT | EMA, FDA, Health Canada |
Organization relationships (15)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Fortrea Holdings Inc. | Uses vendor | 2 |
| Red Nucleus Enterprise Solutions, LLC | Co sponsors trial with | 1 |
| Ryans Quest Inc. | Co sponsors trial with | 1 |
| Opera CRO, a TIGERMED Group Company | Co sponsors trial with | 1 |
| Syneos Health (United States) | Uses vendor | 1 |
Showing 5 of 15 relationships.
Latest dated events (184)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 184 events.
Biomarker capability evidence (138)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| CD19 | Trial sponsor | Named in trial inclusion criteria |
| CD5 | Trial sponsor | Named in trial inclusion criteria |
| CRP | Trial sponsor | Named in trial inclusion criteria |
| DMD | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 138 evidence rows.
On Scientist.com
ITALFARMACO S.P.A. is linked to 3 research suppliers in the Scientist.com network.
Service areas
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Chemi on Scientist.com
For prices, more details, or to contact Chemi, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.